Algert Global LLC Has $2.18 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Algert Global LLC grew its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 18.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 353,133 shares of the biotechnology company’s stock after purchasing an additional 55,311 shares during the period. Algert Global LLC’s holdings in BioCryst Pharmaceuticals were worth $2,182,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in BCRX. The Manufacturers Life Insurance Company raised its stake in BioCryst Pharmaceuticals by 113.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 212,581 shares of the biotechnology company’s stock worth $1,314,000 after buying an additional 113,152 shares during the period. Deerfield Management Company L.P. Series C increased its holdings in shares of BioCryst Pharmaceuticals by 62.9% during the second quarter. Deerfield Management Company L.P. Series C now owns 8,135,804 shares of the biotechnology company’s stock valued at $50,279,000 after acquiring an additional 3,140,804 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 18.8% in the 2nd quarter. AQR Capital Management LLC now owns 543,241 shares of the biotechnology company’s stock worth $3,357,000 after purchasing an additional 85,871 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at $449,000. Finally, Point72 Europe London LLP bought a new stake in BioCryst Pharmaceuticals during the 2nd quarter valued at $1,654,000. Institutional investors own 85.88% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on BCRX. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Finally, JMP Securities increased their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $14.17.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $7.38 on Thursday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88. The stock’s fifty day moving average price is $7.83 and its two-hundred day moving average price is $6.48. The firm has a market cap of $1.52 billion, a PE ratio of -6.90 and a beta of 1.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.11. The firm had revenue of $109.30 million during the quarter, compared to the consensus estimate of $98.30 million. The company’s revenue was up 34.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.24) earnings per share. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.